KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得

Long-term use of rozanolixizumab in generalised myasthenia gravis: final pooled analysis of the phase III MycarinG study and two open-label extensions.

Vera Bril, Artur Drużdż, Julian Grosskreutz, Ali A Habib, Renato Mantegazza, Sabrina Sacconi, Kimiaki Utsugisawa, Tuan Vu, Marion Boehnlein, Fiona Grimson, Niamh Houston, Virginie Kerbusch, Irene Pulido-Valdeolivas, Thaïs Tarancón, John Vissing

Ther Adv Neurol Disord 19 17562864261458532

PMID42388397
PMCIDPMC13319577
DOI10.1177/17562864261458532
发表日期2026-07-02
AI 判定该论文不进入自动 KM 提取:This is a pooled analysis of a Phase III RCT and open-label extensions; it is not a single Phase III RCT itself. The analysis combines data from multiple study designs, including non-randomized open-label extension data.
摘要

摘要

BACKGROUND: Myasthenia gravis (MG) is a rare autoimmune disease characterised by fluctuating and fatigable muscle weakness. In the randomised, double-blind phase III MycarinG study, one 6-week rozanolixizumab cycle significantly improved MG-specific outcomes versus placebo and was generally well tolerated in patients with generalised MG (gMG). OBJECTIVES: To assess the efficacy and safety of cyclic rozanolixizumab treatment. DESIGN: A pooled analysis of the MycarinG, MG0004 and MG0007 studies. METHODS: Following MycarinG, eligible patients could enrol in the open-label extension studies MG0004 or MG0007 to receive rozanolixizumab 7 or 10 mg/kg. In MG0004, patients received chronic weekly treatment for ⩽52 weeks. In MG0007, after an initial 6-week treatment cycle, subsequent cycles were based on symptom worsening (investigator's discretion). Final efficacy data were pooled across MycarinG, MG0004 (first 6 weeks) and MG0007 for patients receiving ⩾2 symptom-driven cycles. Efficacy endpoints included change from baseline (CFB) in MG Activities of Daily Living (MG-ADL), MG Composite (MGC) and Quantitative MG (QMG) scores. Safety outcomes were assessed in patients who received ⩾1 cycle with a ⩽8-week follow-up period across MycarinG and MG0007. RESULTS: Overall, 188 patients received ⩾1 cycle and 129 received ⩾2 symptom-driven cycles. Across Cycles 1-13, mean (standard deviation) CFB to Day 43 in MG-ADL score ranged from -3.2 (3.3 (n = 113; Cycle 3)) to -6.0 (3.9 (n = 24; Cycle 12)). Consistent improvements in MGC and QMG scores were also observed across repeated cycles. Treatment-emergent adverse events (TEAEs) were experienced by 175/188 (93.1%) patients; most mild or moderate. Incidence remained stable with repeated cyclic treatment among patients who remained in the study at each cycle. The most common TEAE was headache (n = 94/188 (50.0%)). CONCLUSION: Repeated rozanolixizumab treatment cycles demonstrated consistent, clinically meaningful improvements in MG-specific outcomes as early as 1 week after the first infusion. Rozanolixizumab was generally well tolerated with an acceptable safety profile, supporting its long-term use as a treatment option for adults with gMG. TRIAL REGISTRATION: ClinicalTrials.gov: NCT03971422; NCT04124965; NCT04650854.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(6,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.Patient disposition of primary efficacy and safety pools. * N numbers assigned in Cycle 1. † After the initial cycle, dose modifications from 10 to 7 mg/kg and vice versa were permitted at the beginning of each treatment cycle, provided the benefit–risk ratio remained favourable for the patient. OLE, open-label extension; RLZ, rozanolixizumab.
非 KM Figure
Figure 2.Mean change from baseline to Day 43 in (a) MG-ADL, (b) MGC, (c) QMG, (d) MG symptoms PRO Muscle Weakness Fatigability, (e) MG Symptoms PRO Physical Fatigue and (f) MG Symptoms PRO Bulbar Muscle Weakness scores. Primary efficacy pool. Efficacy data collected at or after the time point of rescue use were excluded from the analysis with no imputation of missing data for the respective cycle. The reference values for meaningful change were a 2-point improvement for MG-ADL and a 3-point improvement for MGC and QMG. The reference values for meaningful within-patient change for the MG Symptoms PRO scales were a 16.67-point improvement for Muscle Weakness Fatigability and a 20.00-point improvement for Physical Fatigue and Bulbar Muscle Weakness. BL, baseline; CFB, change from baseline; MG Symptoms PRO, Myasthenia Gravis Symptoms Patient-Reported Outcome; MG-ADL, Myasthenia Gravis Activities of Daily Living; MGC, Myasthenia Gravis Composite; QMG, Quantitative Myasthenia Gravis.
非 KM Figure
Figure 3.Mean change from baseline in MG-ADL score to Week 130. Pool E3; consisting of patients who received ⩾2 consecutive symptom-driven treatment cycles. Data at Weeks 0–6 represent observed MG-ADL scores in the Cycle 1 treatment period. After this, patients followed their own cadence of rozanolixizumab treatment cycles, with average monthly (28-day) MG-ADL scores calculated for each patient. The group-level average was calculated using data from all patients with at least one MG-ADL measurement at that time period. If patients had multiple MG-ADL measurements during the period, their average MG-ADL score over the measurements was used. CFB, change from baseline; MG-ADL, Myasthenia Gravis Activities of Daily Living; RLZ, rozanolixizumab; SE, standard error.
非 KM Figure
Figure 4.Responder rates at Day 43 during each cycle for (a) MG-ADL, (b) MGC and (c) QMG scores. Primary efficacy pool. MG-ADL, MGC and QMG response are defined as a ⩾2-point, ⩾3-point and ⩾3-point improvement in score from baseline, respectively, without rescue therapy. * N represents the number of patients who had completed an MG-ADL, MGC or QMG assessment at Day 43 in each treatment cycle. MG-ADL, Myasthenia Gravis Activities of Daily Living; MGC, Myasthenia Gravis Composite; QMG, Quantitative Myasthenia Gravis; RLZ, rozanolixizumab.
非 KM Figure
Figure 5.Frequency of treatment-free intervals. Pool E2; consisting of patients who received rozanolixizumab treatment and had initiated or were awaiting a symptom-driven treatment cycle. Patients without a symptom-driven cycle after rozanolixizumab treatment were censored at the time of dropping out or at the end of the study (MycarinG or MG0007). Number of censored patients: Time to Cycle 1, n = 21; time between Cycles 1 and 2, n = 29; time between Cycles 2 and 3, n = 18; time between Cycles 3 and 4, n = 6; time between Cycles 4 and 5, n = 7; time between Cycles 5 and 6, n = 6; time between Cycles 6 and 7, n = 11; time between Cycles 7 and 8, n = 12; time between Cycles 8 and 9, n = 7; time between Cycles 9 and 10, n = 12; time between Cycles 10 and 11, n = 8; time between Cycles 11 and 12, n = 7; time between Cycles 12 and 13, n = 11; time between Cycles 13 and 14, n = 4.
非 KM Figure
Figure 6.Median percentage change from baseline in total IgG serum concentration. Primary efficacy pool. BL, baseline; CFB, change from baseline; IgG, immunoglobulin.
非 KM Figure